Hyris Brings to Market Worldwide a New Test That Can Quickly Detect the Body's T-Cell Immune Response to SARS-CoV-2, Thanks to a Partnership With Singapore's Duke-NUS Medical
14 oct. 2021 07h50 HE
|
Hyris
LONDON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- After almost two years of fight against COVID-19, governments, NGOs, and corporations are now focusing on strategies and solutions to boost population...
Hyris Brings to Market Worldwide a New Test That Can Quickly Detect the Body's T-Cell Immune Response to SARS-CoV-2, Thanks to a Partnership With Singapore's Duke-NUS Medical
14 oct. 2021 04h00 HE
|
Hyris
LONDON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- After almost two years of fight against COVID-19, governments, NGOs, and corporations are now focusing on strategies and solutions to boost population...
Healthy Directions’ LifeBiome Rise Provides “Always On” Lifestyles a Better Way to Manage the Balancing Act
08 sept. 2021 12h44 HE
|
Healthy Directions
BETHESDA, Md., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Going back to school will be more than a balancing act for parents and students this fall with the feeling that we are not quite out of the woods...
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
11 mars 2021 07h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be...
Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
13 févr. 2020 12h56 HE
|
Amarillo Biosciences, Inc.
Amarillo, TX, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China...
Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services
10 févr. 2020 08h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life...
Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels
24 sept. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO)
18 sept. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific organization that promotes proteomics through international...
Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)
04 sept. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of...
Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting
30 juil. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...